Pasithea Therapeutics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1111 Lincoln Rd Ste 500, Miami Beach, Fl...Phone Number
(786) 977-3380Website
www.pasithea.comRevenue
-Stock Symbol
KTTAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Explore more
Pasithea Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pasithea Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Pasithea Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Pasithea Therapeutics has new funding data
Earning: See what the market has to say on Pasithea Therapeutics recently announced quarterly report
Click to see if Pasithea Therapeutics had a recent Job posting/layoffs
Check out if Pasithea Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Pasithea Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Pasithea Therapeutics
Product Launch: Get notified when Pasithea Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Pasithea Therapeutics
Compare insights from companies similar to Pasithea Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pasithea Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pasithea Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pasithea Therapeutics.
Pasithea Therapeutics financials insights
Gather financial insights about Pasithea Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$695K
Pasithea Therapeutics Tech Stack
A closer look at the technologies used by Pasithea Therapeutics
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Person-Based
Person-Based
Person-Based
Pasithea Therapeutics News & Media
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical TrialPasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF ConferencePasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)Pasithea Therapeutics (NASDAQ: KTTA) names Chief Medical Officer as reporting insider on Form 3
Pasithea Therapeutics files Form 3 identifying Chief Medical Officer Kartik Krishnan as a reporting insider, with no KTTA share transactions or holdings detailed in this excerpt.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pasithea Therapeutics
Sign Up For FreeTo access detailed company insights
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopat... Read More
